National Research Corporation logo
National Research Corporation NRC
$ 18.3 -18.08%
report update icon

Quarterly report 2026-Q1
added 05-06-2026

National Research Corporation Balance Sheet 2025-2008 | NRC

Brief overview of National Research Corporation's financial position

The comparison uses five available annual reports from the 2021–2025 interval.

The asset base decreased -14.4%, from $157.5 million to $134.9 million. Resources became smaller over the five periods.

Funding shifted toward liabilities: they gained +67.4%, compared with -14.4% for assets.

Internal capital represents 10.4% of the balance sheet versus 54.2% five periods ago. The cushion is thin.

Net debt to equity is high at 5.1x; refinancing risk and borrowing costs become more important.

The cash reserve occupies 3.1% of the balance sheet, previously 34.5%. It is one marker of short-term resilience.

Retained earnings are negative at -$17.3 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Balance sheet takeaway

Taken together, National Research Corporation's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.

Annual Balance Sheet National Research Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

71.3 M 54.2 M 23.4 M -2.71 M -27.7 M -8.14 M 20.7 M 24.9 M -33.6 M -29.5 M -36.4 M -32 M -11.8 M 4.48 M 6.4 M - - -

Long Term Debt

75 M 57.9 M 29.5 M 22.3 M 26.6 M 26.5 M 29.8 M 34.2 M - 857 K 3.34 M 5.74 M 8.07 M - 12.6 M - - -

Long Term Debt Current

451 K 550 K 581 K - - - - - - 2.68 M 2.4 M 2.33 M 2.26 M 12.4 M - - - -

Total Non Current Liabilities

- - - - - - 39.6 M 41.8 M 4.96 M 6.3 M 10.7 M 13.8 M 15.6 M 8.01 M 20.7 M - - -

Total Current Liabilities

36.6 M 35.9 M 36.2 M 33.4 M 40.4 M 31.7 M 38.2 M 47.1 M 32.3 M 31.5 M 44.2 M 27.9 M 23.7 M 35.3 M 24.4 M 26.2 M - -

Total Liabilities

121 M 101 M 73.5 M 58.4 M 72.2 M 69.1 M 77.8 M 88.9 M 37.3 M 37.8 M 54.9 M 41.8 M 39.2 M 43.3 M 45.1 M 47.2 M - -

Deferred Revenue

16.2 M 15.8 M 14.8 M 15.2 M 17.2 M 15.6 M 16.4 M 16.2 M 16.9 M 15.5 M 14.8 M 15.1 M 13.9 M 15.8 M 16.5 M 17.7 M - -

Retained Earnings

-17.3 M -17.1 M -30.5 M -25.2 M -36.1 M -61.4 M -93.4 M -106 M 77.6 M 71.5 M 65.3 M 73.7 M 58 M 44.7 M 47 M 41.3 M - -

Total Assets

135 M 133 M 122 M 130 M 158 M 133 M 111 M 108 M 127 M 121 M 129 M 130 M 111 M 100 M 101 M 95.8 M - -

Cash and Cash Equivalents

4.14 M 4.23 M 6.65 M 25 M 54.4 M 34.7 M 13.5 M 13 M 34.7 M 33 M 42.1 M 40 M 22.1 M 8.29 M 8.08 M 3.52 M 2.51 M 1.11 M

Book Value

14 M 31.3 M 49 M 72 M 85.3 M 64.3 M 32.9 M 19.1 M 90 M 82.8 M 74.2 M 87.7 M 71.8 M 56.7 M 55.6 M 48.6 M - -

Total Shareholders Equity

14 M 31.3 M 49 M 72 M 85.3 M 64.3 M 32.9 M 19.1 M 90 M 82.8 M 74.2 M 87.7 M 71.8 M 56.7 M 55.6 M 48.6 M 44.2 M 38.6 M

All numbers in USD currency

Quarterly Balance Sheet National Research Corporation

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

74 M 76 M 77 M 58.7 M 57.9 M 44.9 M 25.7 M - 29.5 M 18.9 M 20.1 M 21.2 M 22.3 M 23.4 M - 25.6 M 26.6 M 27.7 M 28.7 M 25.5 M 26.5 M 27.6 M 28.6 M 28.6 M 29.8 M 29.8 M 29.8 M 29.8 M 34.2 M 34.2 M 34.2 M 34.2 M 1.07 M 1.07 M 1.07 M 1.07 M 857 K 3.54 M 3.54 M 3.54 M 3.34 M 5.74 M 5.74 M 5.74 M 5.74 M 8.07 M 8.07 M 8.07 M 8.07 M 10.3 M 10.3 M 10.3 M 12.4 M 12.4 M 12.4 M 12.4 M 14.5 M 14.5 M 14.5 M -

Total Liabilities

121 M 121 M 120 M 106 M 101 M 97.2 M 78.9 M - 73.5 M 62.3 M 55.9 M 59.6 M 58.4 M 67.2 M - 71.7 M 72.2 M 73.1 M 75.5 M 73.6 M 69.1 M 69.1 M 69.1 M 69.1 M 77.8 M 77.8 M 77.8 M 77.8 M 88.9 M 88.9 M 88.9 M 88.9 M 37.3 M 37.3 M 37.3 M 37.3 M 37.8 M 37.8 M 37.8 M 37.8 M 53.8 M 53.8 M 53.8 M 53.8 M 41.8 M 41.8 M 41.8 M 41.8 M 39.3 M 39.3 M 39.3 M 39.2 M 43.3 M 43.3 M 43.3 M 43.3 M 45.1 M 45.1 M 45.1 M 45.1 M

Deferred Revenue

17.2 M 17.8 M 15.6 M 15.5 M 15.8 M 17.3 M 14.5 M - 14.8 M 16.2 M 14.8 M 15.9 M 15.2 M 17.4 M - 16.7 M 17.2 M 17.3 M 16.8 M 17.6 M 15.6 M 15.6 M 15.6 M 15.6 M 16.4 M 16.4 M 16.4 M 16.4 M 16.2 M 18.6 M 16.7 M 17 M 16.9 M 18.5 M 16.9 M 16.9 M 15.5 M 15.5 M 15.5 M 15.5 M 14.8 M 14.8 M 14.8 M 14.8 M 15.1 M 15.1 M 15.1 M 15.1 M 13.9 M 13.9 M 13.9 M 13.9 M 15.8 M 15.8 M 15.8 M 15.8 M 16.5 M 16.5 M 16.5 M 16.5 M

Retained Earnings

-17.7 M -15.5 M -16.9 M -14 M -17.1 M -20.9 M -23.7 M - -30.5 M -36.5 M -16.8 M -21.2 M -25.2 M -28.9 M - -33.6 M -36.1 M -42.7 M -49.3 M -52.1 M -61.4 M -61.4 M -61.4 M -61.4 M -93.4 M -93.4 M -93.4 M -93.4 M -106 M -106 M -106 M -106 M 77.6 M 77.6 M 77.6 M 77.6 M 71.5 M 71.5 M 71.5 M 71.5 M 65.3 M 65.3 M 65.3 M 65.3 M 73.7 M 73.7 M 73.7 M 73.7 M 58 M 58 M 58 M 58 M 44.7 M 44.7 M 51.3 M 44.7 M 47 M 47 M 47 M 47 M

Total Assets

135 M 136 M 141 M 135 M 133 M 132 M 119 M - 122 M 120 M 134 M 134 M 130 M 135 M - 153 M 158 M 156 M 152 M 147 M 133 M 133 M 133 M 133 M 111 M 111 M 111 M 111 M 108 M 108 M 108 M 108 M 127 M 127 M 127 M 127 M 121 M 121 M 121 M 121 M 128 M 128 M 128 M 128 M 130 M 130 M 130 M 130 M 111 M 111 M 111 M 111 M 100 M 100 M 100 M 100 M 101 M 101 M 101 M 101 M

Cash and Cash Equivalents

2.55 M 2.22 M 5.27 M 2.5 M 4.23 M 3.46 M 485 K - 6.65 M 3.83 M 22.5 M 23.7 M 25 M 28.4 M - 47.3 M 54.4 M 52.5 M 48.9 M 43.5 M 34.7 M 34.7 M 34.7 M 34.7 M 13.5 M 13.5 M 13.5 M 13.5 M 13 M 13 M 13 M 13 M 34.7 M 34.7 M 34.7 M 34.7 M 33 M 33 M 33 M 33 M 42.1 M 42.1 M 42.1 M 42.1 M 40 M 40 M 40 M 40 M 22.1 M 22.1 M 22.1 M 22.1 M 8.29 M 8.29 M 8.29 M 8.29 M 8.08 M 8.08 M 8.08 M 8.08 M

Book Value

13.5 M 14.3 M 21.3 M 29.7 M 31.3 M 34.6 M 40.2 M - 49 M 57.9 M 77.8 M 74.7 M 72 M 67.8 M - 81.5 M 85.3 M 83.1 M 76.4 M 73.2 M 64.3 M 64.3 M 64.3 M 64.3 M 32.9 M 32.9 M 32.9 M 32.9 M 19.1 M 19.1 M 19.1 M 19.1 M 90 M 90 M 90 M 90 M 82.8 M 82.8 M 82.8 M 82.8 M 74.2 M 74.2 M 74.2 M 74.2 M 87.7 M 87.7 M 87.7 M 87.7 M 71.8 M 71.8 M 71.8 M 71.8 M 56.7 M 56.7 M 56.7 M 56.7 M 55.6 M 55.6 M 55.6 M 55.6 M

Total Shareholders Equity

13.5 M 14.3 M 21.3 M 29.7 M 31.3 M 34.6 M 40.2 M 36.9 M 49 M 57.9 M 77.8 M 74.7 M 72 M 67.8 M 68.6 M 81.5 M 85.3 M 83.1 M 76.4 M 73.2 M 64.3 M 64.3 M 64.3 M 64.3 M 32.9 M 32.9 M 32.9 M 32.9 M 19.1 M 19.1 M 19.1 M 19.1 M 90 M 90 M 90 M 90 M 82.8 M 82.8 M 82.8 M 82.8 M 74.2 M 74.2 M 74.2 M 74.2 M 87.7 M 87.7 M 87.7 M 87.7 M 71.8 M 71.8 M 71.8 M 71.8 M 56.7 M 56.7 M 56.7 M 56.7 M 55.6 M 55.6 M 55.6 M 55.6 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of National Research Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA